Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study - PubMed
6 hours ago
- #Atezolizumab-Bevacizumab
- #Real-World Evidence
- #Hepatocellular Carcinoma
- Study evaluates long-term outcomes of atezolizumab-bevacizumab (AB) in unresectable hepatocellular carcinoma (HCC).
- Median overall survival (OS) was 19.7 months with a 36-month survival rate of 30.0%.
- Key factors influencing OS included ECOG-PS >0, ALBI grade >1, AFP >400 ng/mL, multinodularity, macrovascular invasion, and on-treatment events.
- Grade ≥3 adverse events occurred in 36.8% of patients, with five late-onset severe toxicities beyond 24 months.
- Liver decompensation unrelated to tumor progression occurred in 14.1% of patients.
- 14.9% of patients underwent surgical or locoregional procedures post-AB initiation; 4.4% achieved drug-free disease-free status.
- Findings confirm sustained effectiveness of AB without new safety concerns.
- Highlights the need for a multidisciplinary approach in advanced HCC management.